• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Latest News about UCBJY

Recent news which mentions UCBJY

RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program
August 06, 2025
Tickers AMGN BMY JNJ LLY
Tags JNJ SNY UCBJF
From Benzinga
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results
June 12, 2025
Tickers BIIB NEWS UCBJF UCBJY
Tags BIIB News Benzinga
From Benzinga
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study
May 09, 2025
Tickers JNJ NEWS NVS PTGX
Tags UCBJY Market News Large Cap
From Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
April 09, 2025
Tickers ARGX AZN GILD GSK
Tags REGN UCBJY RDY
From Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
March 21, 2025
Tickers AMGN AZN BIIB BMY
Tags PFE UCBJF AZN
From Benzinga
Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders
March 07, 2025
Tickers NEWS UCBJF UCBJY
Tags Large Cap Eurozone Biotech
From Benzinga
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
November 20, 2024
Tickers BIIB NEWS UCBJF UCBJY
Tags General Trading Ideas Analyst Ratings
From Benzinga
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
November 20, 2024
Tickers NEWS UCBJF UCBJY
Tags Benzinga Stories That Matter Top Stories
From Benzinga
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
September 24, 2024
Tickers BIIB NEWS UCBJF UCBJY
Tags BIIB Stories That Matter General
From Benzinga
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
September 10, 2024
Tickers LBPH NEWS UCBJF UCBJY
Tags Stories That Matter epilepsy General
From Benzinga
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
August 29, 2024
Tickers ARGX JNJ NEWS UCBJF
Tags Stories That Matter JNJ UCBJF
From Benzinga
Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies
August 26, 2024
Tickers NEWS UCBJF UCBJY
Tags Health Care Biotech Briefs
From Benzinga
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
January 02, 2024
Tickers LBPH NEWS UCBJF UCBJY
Tags Benzinga LBPH News
From Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
September 28, 2023
Tickers AZN DNTH SNY UCBJF
Tags Benzinga Initiation News
From Benzinga
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
August 31, 2023
Tickers MLTX SLRN UCBJF UCBJY
Tags Health Care Biotech Briefs
From Benzinga
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
June 27, 2023
Tickers ARGX UCBJF UCBJY
Tags News Benzinga ARGX
From Benzinga
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
February 14, 2023
Tickers MLTX NVS UCBJF UCBJY
Tags Movers MLTX UCBJF
From Benzinga
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
May 30, 2022
Tickers ABBV ALPN AUPH BLCO
Tags VRCA IBB General
From Benzinga
‘The capitulation model for biotech is a Category 5 storm, the same as energy in 2020’ — why contrarians say the sector is a buy
May 20, 2022
Tickers BMY FATE IBB JNJ
Tags JNJ BMY PFE
From MarketWatch
UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
March 28, 2022
Tickers UCBJF UCBJY
Tags FDA Health Care Biotech
From Benzinga
Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane
February 08, 2022
Tickers BIIB UCBJF UCBJY
Tags Benzinga News BIIB
From Benzinga
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
January 23, 2022
Tickers ABT CUE DCPH ETON
Tags Top Stories IPOs ABT
From Benzinga
UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study
January 21, 2022
Tickers UCBJF UCBJY
Tags News Phase 3 Trial Health Care
From Benzinga
ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today
January 19, 2022
Tickers SOFI SONY UCBJY ZGNX
Tags UCBJY ZGNX SONY
From InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021
September 02, 2021
Tickers ALKS ASMB BLDE CATB
Tags Downgrades Initiation ALKS
From Benzinga
UCB Gets EU Approval For Bimekizumab In Psoriasis
August 25, 2021
Tickers NVS UCBJF UCBJY
Tags Movers Psoriasis UCBJF
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2021
August 23, 2021
Tickers ACVA CADL CHK CLR
Tags VEI BZI/Ratings Market News
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021
July 23, 2021
Tickers ADVM AGESY AGFY AHH
Tags Initiation INSE BANC
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 9, 2021
July 09, 2021
Tickers ALGN ARGO ASLN BMBL
Tags Downgrades SAFM TEX
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap